1 Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia and/or Hemoglobinuria following Rh o (D) Immune Globulin Intravenous Administration.

Slides:



Advertisements
Similar presentations
The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Advertisements

Heather D. Mannuel, MD, MBA March 12, 2008
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
ALLOIMMUNIZATION IN PREGNANCY
FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,
What You Need to Know About Acute Chest Syndrome By Susan Hernandez, RN, CNN, BSN, and G. Elaine Patterson, RN-C, EdD, MA, Med, FPN-C Nursing2009, June.
Tessa Bandhan. Question 1 A 3 year old girl known to have sickle cell disease (Hb SS) presents to the Emergency Room with a 2 day history of weakness.
1 Proposed Changes to ICD-9-CM Transfusion Associated Adverse Events September 17th, 2009 ICD-9-CM Coordination and Maintenance Committee Meeting Mikhail.
Chemotherapy/ Biotherapy for Hematology Disease Processes.
Special Topics in IND Regulation
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
BLOOD TRANSFUSION Begashaw M (MD).
THROMBOCYTOPENIA - reduced platelet count -. First of all.. what are platelets? Platelets: tiny cells that circulate in the blood and whose function is.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’
November 23, Idiopathic Throbocytopenic Purpura.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.
CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Serious adverse events following falsely high glucose measurements resulting from administration of an IGIV product containing maltose L. Ross Pierce,
Safety & Efficacy Update on Approved TNF-Blocking Agents Jeffrey N. Siegel, M.D. OTRR, CBER / FDA Arthritis Advisory Committee March 4, 2003 Jeffrey N.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
POSTMARKETING ADVERSE DRUG EXPERIENCE INSPECTIONAL PROGRAM CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
NORTH AMERICAN SAFETY CHECKLIST – SB 158. Rhonda Anderson, RHIA President Anderson Health Information Systems, Inc. Presented By:
What Makes a Good Medical Device Adverse Event Report?
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
Transfusion Emergencies. TRANSFUSION REACTIONS IMMUNOLOGIC NON-IMMUNOLOGIC.
1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
CLS 2215 Principles of Immunohematology
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
Monthly Journal article review: Vimmi Kang PGY 2
FEBRILE NONHEMOLYTIC TRANSFUSION REACTIONS
Transfusion Reactions
Blood grouping Biology 106.
Laboratory Management. ITP is suspected in patients with isolated thrombocytopenia Because manifestations of ITP are nonspecific, other causes of isolated.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
1 TNF Blocker Safety: Lymphoma and Liver Failure Tim Coté MD MPH, Chief, Therapeutics & Blood Safety Branch, DE/OBE/CBER/FDA March 4, 2003.
1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,
Introducing RADAR: The Research on Adverse Drug Events And Reports (RADAR) Project Charles L. Bennett MD, PhD, MPP Feinberg School of Medicine, Northwestern.
Dr: Dalia Galal Hamouda
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
The complications can be broadly classified into two categories: Immune Complications Non-immune Complications.
1 Risk Management Considerations for Romiplostim Suzanne Berkman, PharmD Senior Risk Management Analyst Division of Risk Management Office of Surveillance.
1 INTRODUCTION: Proposed Use of HBOC-201 * in the RESUS (Restore Effective SUrvival in Shock) Trauma Trial Laurence Landow MD, FRCPC Medical Officer, Clinical.
Transfusion Related Acute Lung Injury (TRALI)
Chapter 38 Hematologic Disorders and Oncologic Emergencies Unit 8 Multisystem Alterations Seventh Edition Linda D. Urden Kathleen M. Stacy Mary E. Lough.
Done by : Bara Shayib Supervised by : Dr. Abdullateef Alkhateeb.
Nursing Management: Hematologic Problems Chapter 31 Overview Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc.
1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
By Dr.AMEER E. AL-AASAM. MECHANISM DRUG ADSORPTION (HAPTEN) TERNARY (IMMUNE) COMPLEX AUTOANTIBODY INDUCTION Direct antiglobulin testPositive (anti-IgG)Positive.
TRANSFUSION REACTIONS
Blood Grouping Or Blood Types
From: Parvovirus B19–Related Anemia in an HIV-Infected Patient: Rapid Control after Production of Neutralizing Antibodies during Highly Active Antiretroviral.
CDC Guidelines for Use of QuantiFERON®-TB Gold Test
SERIOUS ADVERSE EVENTS REPORTING
The Hematologic System as a Marker of Organ Dysfunction in Sepsis
Monthly Journal article review: Vimmi Kang PGY 2
Anemia in Adults: A Contemporary Approach to Diagnosis
A diagnostic algorithm for the investigation and management of a patient presenting with thrombotic microangiopathy. A diagnostic algorithm for the investigation.
Presentation transcript:

1 Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia and/or Hemoglobinuria following Rh o (D) Immune Globulin Intravenous Administration for Immune Thrombocytopenic Purpura Ann Gaines, PhD, MT(ASCP) Division of Epidemiology Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research BPAC Meeting, Gaithersburg, MD, July 21, 2005

2 Licensure +Rh o (D) Immune Globulin Intravenous (Human) (anti-D IGIV) licensed on March 24, Licensed as WinRho™; currently marketed as WinRho™ SDF* +Licensed for:  suppression of Rh isoimmunization  treatment of immune thrombocytopenic purpura (ITP) in Rh o (D)-positive, non-splenectomized:  children with acute ITP  children and adults with chronic ITP  children and adults with ITP secondary to HIV infection * manufactured by Cangene Corporation, Winnipeg, Manitoba, Canada

3 Product Description +As listed in professional package insert, anti-D IGIV contains known red blood cell (RBC) antibodies:  high-titered anti-D ?low-titered anti-A, anti-B, anti-C, and anti-E +As reported in literature in 2000, anti-D IGIV may also contain other low-titered RBC antibodies (e.g., anti-Duffy a [anti-Fy a ], anti-Kidd a [anti-Jk a ])

4 Presumed Mechanism of Action in ITP + Extravascular hemolysis of anti-D-sensitized RBCs by splenic macrophages, which results in:  decreased splenic destruction of platelets  increased platelet count +Expected adverse events, consistent with extravascular hemolysis mechanism of action, may include:  decreased hemoglobin concentration  positive direct and indirect antiglobulin tests

5 Postmarketing Surveillance + Routine postmarketing surveillance has detected 2 serious, unexpected anti-D IGIV adverse events since licensure  serious (as defined by FDA): includes life-threatening, medical intervention, among other criteria  unexpected (as defined by FDA): not listed in professional package insert + Both adverse events involve administration of anti-D IGIV for treatment of ITP  acute hemoglobinemia and/or hemoglobinuria  disseminated intravascular coagulation (DIC)

6 Hemoglobinemia and/or Hemoglobinuria +Clinical trials of anti-D IGIV for ITP identified 2 cases of “acute-onset hemoglobinuria consistent with intravascular hemolysis” + Between licensure and present, cases suggestive of acute hemoglobinemia and/or hemoglobinuria (“acute hemolysis”) submitted to FDA’s adverse event reporting system, MedWatch (continued)

7 Hemoglobinemia and/or Hemoglobinuria Cases of acute hemolysis received by FDA through April 1999 included 15 patients, 11 of whom had complications: + 7 developed sufficient anemia to prompt orders for packed RBC transfusions; only 6 transfused + 8 had onset or worsening of renal insufficiency; 2 underwent dialysis + 1 died from pulmonary edema and respiratory distress secondary to exacerbated anemia + 6 had 2-3 of these complications (continued)

8 Hemoglobinemia and/or Hemoglobinuria Review of those 15 cases suggested that acute hemolysis: +Seemed inconsistent with extravascular hemolysis mechanism of action in ITP patients + Seemed consistent with intravascular hemolysis of acute hemolytic transfusion reactions + Remains unexplained in terms of immune-mediated or other mechanisms of hemolysis (continued)

9 Hemoglobinemia and/or Hemoglobinuria Risk communication efforts undertaken: + Cases reported in Blood on April 15, 2000, with suggestion that patients be monitored for:  acute hemolysis, clinically compromising anemia, and renal insufficiency  other potential complications of hemoglobinemia, notably DIC +Revisions to professional package insert distributed by manufacturer with “Dear Healthcare Professional” letter (continued)

10 Disseminated Intravascular Coagulation +Clinical trials of anti-D IGIV for ITP identified no reports of DIC (or any complications) associated with 2 cases of “acute-onset hemoglobinuria consistent with intravascular hemolysis” + Between licensure and present, cases of DIC associated with acute hemolysis submitted to MedWatch (continued)

11 Disseminated Intravascular Coagulation Cases of DIC received by FDA between May 1999 and November 2004 included 6 patients: + 5 died, with DIC or acute hemolysis assessed as having caused or contributed to each death + 4 had onset or worsening of renal insufficiency; 2 underwent dialysis + 4 developed sufficient anemia to prompt packed RBC transfusions + 5 had 2-4 of these complications (continued)

12 Disseminated Intravascular Coagulation Review of those 6 cases suggested that: +DIC seemed consistent with recognized, potential complication of acute hemolysis  Previous uneventful anti-D IGIV administration does not preclude acute hemolysis upon subsequent anti-D IGIV administration (continued)

13 Disseminated Intravascular Coagulation Risk communication efforts undertaken or in progress: + Cases published online in Blood on May 5, 2005,* with suggestion that patients experiencing acute hemolysis be monitored for DIC +Appropriate revisions to professional package insert under consideration * print version scheduled to be published on September 1, 2005

14 Adverse Event Reporting Physicians, other health care professionals, and patients encouraged to submit serious adverse event reports for anti-D IGIV or any FDA-approved product:  to FDA:  by Internet at  by telephone at FDA-1088  by fax at FDA-0178  by mail at MedWatch, HF-2, 5600 Fishers Lane, Rockville, MD to manufacturers or distributors: contact information generally available in professional package inserts or on web sites